Table 1.

Clinical and pathologic features of patients with HNSCC enrolled in phase 0 STAT3 decoy trial

Saline (N = 14)Decoy (N = 16)
Age, y51.4 ± 15.463.6 ± 15.1
Sex (male:female)8:613:3
Race (% white)8688
Site, n
 Oral cavity119
 Pharynx02
 Larynx35
Primary:recurrent tumor12:29:7
T stage, n
 160
 226
 301
 442
N stage, n
 094
 113
 222
Prior HNSCC treatment, n
 Surgery04
 Radiation28
 Chemotherapy12
 Biologic (cetuximab)03
Time between pre- and posttreatment biopsies, h4.1 ± 2.74.5 ± 2.1